Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bavituximab - Avid Bioservices

Drug Profile

Bavituximab - Avid Bioservices

Alternative Names: 3G4; Anti-phosphatidylserine monoclonal antibody 3G4; Anti-phospholipid monoclonal antibody 3G4; Anti-PS MAb 3G4; Monoclonal antibody 3G4; Tarvacin

Latest Information Update: 15 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Avid Bioservices; University of Texas M. D. Anderson Cancer Center
  • Developer Avid Bioservices; IMV; Massachusetts General Hospital; Merck Sharp & Dohme; Oncologie; Peregrine Pharmaceuticals; University of Arizona; University of Texas Southwestern Medical Center
  • Class Adjuvants; Antineoplastics; Antivirals; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Antibody-dependent cell cytotoxicity; Phosphatidylserine receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Non-small cell lung cancer
  • Phase II Gastric cancer; Glioblastoma; Liver cancer; Oesophageal cancer
  • Preclinical Solid tumours
  • Suspended Breast cancer; Malignant melanoma; Pancreatic cancer
  • No development reported Brain cancer; Hepatitis C; HIV infections; Rectal cancer; Viral haemorrhagic fevers
  • Discontinued Influenza virus infections; Prostate cancer

Most Recent Events

  • 11 Nov 2019 University of Maryland and Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins plan a phase II trial for Head and neck cancer (Metastatic disease, Recurrent, Combination therapy, Second-line therapy or greater) in USA (IV), in January 2020 , (NCT04150900)
  • 15 Oct 2019 Oncologie and Merck Sharp & Dohme initiates enrollment in a phase II trial for Gastric cancer and Oesophageal cancer (Combination therapy, Second-line therapy or greater, Inoperable/Unresectable, Metastatic disease, Late-stage disease) in USA (IV) (NCT04099641)
  • 11 Sep 2019 Phase-II clinical trials in Gastric cancer (Combination therapy, Second-line therapy or greater, Inoperable/Unresectable, Metastatic disease, Late-stage disease) in USA (IV) (NCT04099641)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top